Inhibitory effect of Weissella cibaria isolates on the production of volatile sulphur compounds

Aims: The objective of this study was to characterize the inhibitory effects of Weissella cibaria isolates on volatile sulphur compounds (VSC) production both in vitro and in vivo. Material and Methods: We isolated and identified three hydrogen peroxide‐generating lactobacilli from children's s...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical periodontology Vol. 33; no. 3; pp. 226 - 232
Main Authors Kang, Mi-Sun, Kim, Byung-Gook, Chung, Jin, Lee, Hyun-Chul, Oh, Jong-Suk
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.03.2006
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Aims: The objective of this study was to characterize the inhibitory effects of Weissella cibaria isolates on volatile sulphur compounds (VSC) production both in vitro and in vivo. Material and Methods: We isolated and identified three hydrogen peroxide‐generating lactobacilli from children's saliva, and assessed their inhibitory effects on VSC production and Fusobacterium nucleatum proliferation. Clinical studies were conducted with 46 subjects in order to measure the VSC of their mouth air. Results: These lactobacilli were identified as W. cibaria. These isolates inhibited the production of VSC by F. nucleatum (p<0.05). The concentration of F. nucleatum was decreased by 5‐log cycles as a result of exposure to the W. cibaria strains (p<0.05), whereas the catalase‐treated W. cibaria cultures exerted no evident inhibitory effects on F. nucleatum replication. In the clinical studies, gargling with one isolate resulted in a significant reduction in the levels of H2S and CH3SH by approximately 48.2% (p<0.01) and 59.4% (p<0.05), respectively. Conclusions: These results indicate that W. cibaria isolates possess the ability to inhibit VSC production under both in vitro and in vivo conditions, demonstrating that they bear the potential for development into novel probiotics for use in the oral cavity.
Bibliography:istex:E1BE1730D75BAECE0B3598EDC0FC554660CC136A
ark:/67375/WNG-TDPZCV7M-V
ArticleID:JCPE893
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0303-6979
1600-051X
DOI:10.1111/j.1600-051X.2006.00893.x